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Abstract

Drug development is a rigorous and expensive process that takes between 10 and15 years.
Recruitment and retention of human subjects in clinical trials is challenging. This study collected
the demographics of trial participant in trials for New Molecular Entities (NMEs) approved by
the U.S. Food Drug Administration (FDA) for 2010 and 2020 to compare demographic
representation. Demographic representation of trial participants for 61 FDA-approved NMEs for
2010 and 2020 were gathered; 21 NMEs were excluded from analysis. The trends in
demographic representation in trials for the 40 FDA-approved NMEs in 2010 and 2020 were
similar, and White participant representation was higher than racial/ethnic minorities. This study
was limited by inconsistent reporting of demographic categories such as age and ethnic groups.
Recruitment of racial/ethnic minorities remains persistently low, which affects the diversity of
drug development programs. There is a compelling need for further research.
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Introduction

Drug development is a rigorous, lengthy, and costly process that takes between 10 to 15
years from the preclinical (bench) to Phase IV (bedside), when the drug gets to the market after
obtaining approval from the relevant regulatory authorities; the cost of this process is about $2
billion. The recruitment of the actual calculated sample size for clinical trials in a specified time
has been a barrier in the drug development process (Chaudhari et al., 2020). This delay leads to
the inability of meeting the clinical trial’s deadline, which leads to the rise in the cost and an
increase in the time, which affects other aspects of the clinical trials.

According to a report analysing global data of clinical trials that were stopped in the
clinical database, 55% of the clinical trials were discontinued because of a substantially lower
rate of human subjects completing the clinical trials (Desai, 2020). The efficiency of the average
recruitment of human subjects is reported to be < 40% for Phase III and Phase IV of clinical
trials. More than 80% of clinical trials worldwide fail to recruit human subjects within the
specified time, leading to prolongation of the clinical study time and/or requiring more clinical
study sites (Desai, 2020). Inadequate retention of human subjects to the clinical study closeout is
a problem because there may be an inadequate number of research participants that will be able
to answer the research questions properly. The low statistical power for clinical trials affects the
validity of the result, and this has economic, ethical effects and also leads to delays in the clinical
trials (Desai, 2020; Ross et al., 1999).

DEMOGRAPHIC PROFILES OF CLINICAL RESEARCH PARTICIPANTS

2

Statement of the Problem

There are several barriers that the pharmaceutical/biotechnology industries, clinical
research organizations (CROs), and research professionals encounter during the recruitment of
human subjects and their retention in clinical trials. The lack of adequate and diverse clinical trial
participants in clinical trials has contributed to many failed trials, loss of funds, loss of time, and
lack of validity of the research. Inadequate knowledge of clinical trials by the clinical trial
participants and lack of awareness have been a challenge. Also, the inadequate recruitment of
women and racial/ethnic minorities is a barrier to clinical trial recruitment and retention.
Understanding the demographic profiles of research subjects is crucial to the success of the
recruitment and retention of human subjects in clinical trials, and this contributes immensely to
the success of clinical trials during the drug development program, which helps to develop novel
therapeutics for patients.

Purpose of the Study

The purpose of my research is to further assess the demographic profiles of the
population in my environment to understand the demographics of the population that have
participated in clinical research, and the reason why people may like to participate. Several
factors affect the human subjects in participating in clinical trials such as ethnicity, their level of
education, the level of exposure to clinical trials, socioeconomic status, distance to clinical trial
sites, and the association between their social status and their participation in clinical trials. This
research gathered the demographic data-age; gender; race: White, Black/African American,
Asian/Asian American, or mixed race/multiple races; and ethnicity (Hispanic, Latino, nonHispanic) of clinical trial participants from the reported clinical trials (Phase II, Phase III, and
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Pivotal trials) that were conducted for the 61 New Molecular Entities (NMEs) approved by the
United States Food and Drug Administration (FDA) for 2010 and 2020. The demographic data
gathered will help us to understand the recruitment and retention of clinical trial participants in
clinical trials during drug development programs. This will provide more information on the
demographic profile of the trial participants’ representations, which can help to further develop
more strategies to improve the inclusion of a more diverse population in clinical trials and to
develop more strategies to improve the retention of clinical trial participants in clinical trials
during the drug development programs.

Significance of the Study

The demographic variable data (age, gender, race, and ethnicity) of the clinical trial
participants were gathered from the clinical trials conducted for the 61 FDA-approved NMEs for
2010 and 2020. This information will allow the research professionals, pharmaceutical/
biotechnology industries, clinical research organizations, and other interested organizations to
gain deeper knowledge on the recruitment and retention of the trial participants, especially the
racial/ethnic minorities’ clinical trial participants. This information is crucial because it will help
research professionals, pharmaceutical/biotechnology industries, and other relevant organizations
to develop more strategies to improve the recruitment and retention of trial participants,
especially the racial/ethnic minority participants in clinical trials during the drug development
programs. It is important to have a more diverse population in the clinical trials, which will help
us to gain more knowledge on the safety and efficacy of the novel drugs and to increase the
application of the drugs to a more diverse population.
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Review of Literature

About 30% of the duration of the drug development program is taken up by the
recruitment of human subjects; this costs around 1.2 billion USD (Pateria & Singh, 2015). There
are obstacles in recruiting human subjects for clinical trials which range from one to six months
delay in most clinical trials; some other pharmaceutical industries and clinical research
organizations, encounter longer delays in recruiting human subjects, and these delays cost
pharmaceutical industries to lose between $600,000 and $8 million each day of the delay (Ray &
Tosti, 2017). About 11% of the clinical study sites failed to recruit one clinical human subject,
and 37% of the clinical research sites are under-recruiting research subjects. This has led to
inefficiency and reduction in the productive capacity, loss of funds, and time which affects the
sponsors and other relevant partners in the drug development program (Ray & Tosti, 2017).
Human subjects’ recruitment and retention in clinical trials are the main obstacles in clinical
trials, and these are very important because of the financial implications and validity of the
study.

Appropriate strategies for recruitment and retention of human subjects in clinical trials
and effective communication with relevant partners during the drug development program will
help to prevent unnecessary delays in the drug development program, which will help create an
efficient and organized process, allowing the pharmaceutical industries to make the new products
available at the scheduled time at a cheaper price. Appropriate recognition of the possible
problems and evaluation of the plans for both the recruitment and retention of human subjects in
clinical trials can help to increase the recruitment and retention of clinical trial participants in
drug development programs (Chaudhari et al., 2020).
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Furthermore, there are strategies to improve the recruitment of the human subjects in
clinical trials such as having a good knowledge of the patients’ experiences and addressing them
in the clinical study plans, by conducting a focus group discussions and surveys, interviewing the
patients and medical personnel (physicians) and integrating their responses when designing the
protocols and developing the study tool to reduce amendment of protocols, and increasing both
patients and investigators commitment. Planning the protocol well in advance and having a wellplanned enrollment method will facilitate the identification, assessment, and control of the
threats associated with the human subjects’ recruitment (Ray & Tosti, 2020).

Recruitment of human subjects should be done appropriately in an ethical manner. The
investigators should actively identify the human subjects that are suitable for enrollment in the
clinical trial, the human subject should be selected in line with the trial protocol and all human
subjects recruited into the study must meet the protocol requirements. The recruitment and the
recruitment advertisement materials must be approved by the institutional review board (IRB) or
independent ethics committee (ICH GCP 3.1.2), and the potential benefits, risks and other
options of the intervention of the study should be presented to the potential research participants
before the enrollment to determine their interest and agreement to participate (Shah et al., 2022);
this is regarded by the federal regulations and IRB as the beginning of Informed Consent
process.

According to the good clinical practice (GCP), the two major elements of recruitment are
defining a population of suitable research participants to respond to the research questions and
ethically recruiting suitable human subjects. The research subjects should be recruited in line
with the 1979 Belmont Report, which is based on the three fundamental principles that are
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focused on the present system of human research protection; respect for persons, beneficence,
and justice (Sims, 2010).

Retention of human subjects in clinical trials is an ongoing process. The clinical trial staff
must ensure that they do their best to retain the clinical trial participants through to the end of the
clinical trial (study closeout) and that they are compliant throughout the study period. These are
the activities done by the clinical trial team to motivate and support the human subjects to stay
enrolled and be involved in the clinical trial. According to GCP, retention of research
participants implies ensuring human subjects submit to the research procedures at the scheduled
time, respond to the sets of questions or the interviewers’ questions, are involved in any other
tasks that the trial protocol requires, and attend follow-up visits as required. The GCP further
outlines elements of a successful retention plan, such as making sure they treat human subjects
with respect, being mindful of the clinical trial participants’ time, recognizing and conquering
the obstacles to retention, including the retention plans in the budget and recognizing, and
dealing with the difficulties promptly (Chaudhari et al., 2020).

Place of residence, race/ethnicity/culture/language, occupation, gender, religion,
education, socioeconomic status, and social capital (PROGRESS) play a crucial role in the
recruitment and retention process in clinical trials (Chaudhari et al., 2020). This research further
outlined frequent explanations that research subjects give for not getting involved in clinical
trials, which are the complexity of the research protocol, sociocultural issues, negativism by the
media, unfavorable clinical trial plans, geographical distance, anxiety regarding the placebo,
benefits of the investigational products, inadequate knowledge of clinical trials, anxiety
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regarding the adverse events, and how some human subjects are been treated may discourage
them from participating in clinical trials (Ross et al., 1999; Chaudhari et al., 2020).

Furthermore, some other difficulties affect the recruitment of human subjects into clinical
trials. There are reports that some women of childbearing age find it difficult to abstain from sex
or use the right type of contraceptives during the period of the clinical trials (Chaudhari et al.,
2020). Other issues include the following: the research participants might like to participate in
clinical trials because of the free medical check-up, the small money that the researchers or
sponsors will offer them for participating in the clinical trials, less educated people may need
more time to understand the process of the clinical trial, and people that are on daily wages are
reported to refuse participation and staying in the hospital for the trials because of loss of wages.
Religious beliefs can be a hindrance; it is noted that clinical trial participants’ recruitment during
the fasting period for Muslims can be slow because of their religious beliefs, but this is more
common in the regions that are largely Muslims. Hospital environments such as the intensive
care unit environment can make some people afraid of participating in Phase I clinical trials,
delayed Data and Safety Monitoring Board (DSMB) reports, and also delayed funds from the
sponsors/clinical research organizations can delay human subjects’ recruitment (Chaudhari et al.,
2020).

The significance of the involvement of racial and ethnic minorities in clinical research is
well recognized, and it contributes to the generalizable knowledge of clinical research. This
ensures that the result of the research can be applied to a heterogeneous population (Yankey et
al., 2006). It allows for justice and fairness in health care delivery and reliability in ethnicity
analyses. It is also reported that there is disproportionately low representation of the racial and
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ethnic minorities in clinical research (George et al., 2014). Over 30% of the population in the
United States are of racial/ethnic minorities’ origin. The National Cancer Institute’s recruitment
of minority subjects was lower than 18% for its publicly funded cancer clinical trials (phase I-III
treatment studies, January 1, 2003 to June 30, 2005), and 17% of the FDA human subjects were
of racial and ethnic minorities in the 185 studies of new molecular entities for a period of five
years (George et al., 2014).
A retrospective review of FDA medical officers’ reviews of clinical trial protocols and
product labeling for 185 new molecular entities (NMEs) approved by the United States FDA
between January 1, 1995, and December 31, 1999, revealed that 17% of the FDA clinical study
human subjects were racial/ethnic minorities (Evelyn et al., 2001). George et al. revealed several
obstacles in recruiting racial and ethnic minorities into clinical research for both the human
subjects and the researchers. Regarding the researchers, a lack of adequate knowledge about
cultural diversity in ethnic minorities can lead to ineffective communication during clinical trials.
Previously, White human subjects have been the “gold standard” for human subjects’
recruitment for clinical trials, but this cannot be generalizable to the general population including
ethnic minorities (George et al., 2014). The health inequalities that affect the racial and ethnic
minorities across the United States regarding their access to health care and undesirable health
outcomes and the Tuskegee Study are known to be part of the obstacles that affect the
involvement of racial and ethnic minorities in clinical research (George et al., 2014; Shavers et
al., 2002).
In line with the national priority to ensure there is diversity in human subjects’
participation in clinical trials, FDA offered New Guidance on Enhancing the Diversity of
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Clinical Trial Populations- Eligibility Criteria, Enrolment Practices, and Trial Designs
Guidance for Industry (U.S. Food and Drug Administration [FDA], 2020a). The guidelines were
set forth by congressional legislation in the early 1990s. These guidelines were established to
include women and promote the recruitment of racial and ethnic minority groups in federally
funded human participant research (Robinson et al., 2017). The FDA endorsed recruitment
practices for clinical trials that reflect the population that will most probably use the drug when
approved, mainly by expanding the eligibility criteria for human subjects’ enrolment. This
guidance takes into consideration the demographic characteristics of the populations to be
studied (e.g., ethnicity, age, sex, race, location of residency) and non-demographic features of the
populations (e.g., comorbid conditions, disabilities, patient with organ dysfunction, those at the
extremes of the weight range, and populations with diseases or conditions with low prevalence).

The FDA- recommended sponsors consider the following when enrolling human subjects
along with other relevant FDA recommendations: (a) During the development of the clinical
study protocol, they should make sure that the eligibility criteria of the trial are indicative of the
sample of the population that the drugs that is been developed is meant for, and it should
scrutinize the exclusion criteria to establish the need to ensure the safety of human subjects and
to achieve the trial objectives. (b) They should take into consideration the exclusion criteria from
Phase II trials, which can be very selective and are frequently, moved to Phase III protocols. This
can be stopped or adapted for Phase III trials because Phase III trials’ objectives are different
from the Phase II trials to avert the needless limitations on the study population. (c) The sponsors
are meant to enroll human subjects that are reflective of the features of clinically appropriate
populations in terms of sex, ethnicity, age, and race (Robinson et al., 2017).
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Baquet et al. further revealed that 32% of Americans would like to participate in clinical
trials if offered and 38% of Americans would consider participating in clinical trials if asked, but
they will have some reservations (Baquet et al., 2006). Other reasons that were reported to affect
participation in clinical trials are racial minority group; older age; lack of suitable clinical trials;
disqualification of patients; lower socioeconomic status; ineffective doctor-patient
communications in regard to clinical trials; apprehension of academic institutions, research, and
the medical system; apprehension of the negative effects of the trials; inadequate knowledge of
the benefits of clinical trials by the community and the physicians; inadequate training of the
researchers in the culturally acceptable communication approaches; patients’ fears regarding the
trials; inadequate access to care; inadequate details regarding the clinical trials; and inadequate
support for the community outreach (Baquet et al., 2006).

Demographic profiles of human subjects in clinical trials are very important for the
analysis of the safety and efficacy of a novel drug. The FDA is in charge of the approval of new
drugs or therapeutics by assessing the clinical trials. The purpose of clinical trials is to make sure
the new drugs or therapeutics are safe and effective in the desired populations that are meant to
use the drugs or therapeutics. The human subjects in the clinical study should be representative
of the patient population the drug or therapeutic is meant for (Sacristán et al., 2016).

Despite the efforts of the FDA, there are reports that racial and ethnic minorities, women,
and older adults are inadequately represented in drug development programs (Chen et al., 2018).
A recent cross-sectional study done on human subjects in the United States vaccine clinical trials
revealed that the older adults and racial/ethnic minority groups had lower representation
compared to the women who were overrepresented in the trials (Flores et al., 2021); there is an
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urgent need to address this inadequate representation in the drug development programs. FDA
evaluates the demographics of human subjects in clinical trials and also does the subgroup
analyses at the time of the regulatory evaluation of new drug and biologic product marketing
applications.

Furthermore, the reports from these clinical studies are utilized to assist the regulatory
decisions for the drug applications, the approved drugs can be used in a substantial and more
diverse population above the population that the novel drug was exposed to during the clinical
trials of the drug development (Chen et al., 2018). The United States FDA has been increasing its
priority on improving the demographic representation in clinical trials, FDA introduced an
“action plan” to enhance the demographic subgroup analysis in the assessment of new drugs/
therapeutics, with definite guidelines to strengthen the quality of demographic data gathered in
post-marketing surveillance systems (FDA, 2020a; FDA, 2014).

Research Questions


What is the demographic profile of clinical participants in drug (NME, new drug
application [NDA]) studies, especially with respect to racial/ethnic minorities?



Has the demographic profile of clinical trial participants in drug development (NME,
NDA) studies changed from 2010 to 2020, especially with respect to racial/ethnic
minorities?



Are racial/ethnic minorities underrepresented in clinical trials?



Are women/females underrepresented in clinical trials?
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Methods

Sample Selection

This research was based on summary demographic data gathered from the reported data
from the United States Food and Drug Administration (FDA) website, under “FDA-Approved
Drugs,” which can be found on the FDA website: Drugs@FDA-Approved Drugs (FDA, 2010;
FDA, 2020). All the data were from clinical trials (Phase II/Phase III), including the Pivotal
studies conducted for FDA-approved New Molecular Entities (NMEs) in 2010 and 2020. The
demographic data were collated from the accessible reported clinical trials. The demographic
variables were age groups, gender/sex (males and females), race (White, Black, Asian,
mixed/multiple races, and others), and ethnicity (Hispanic/Latino, Non-Hispanic/Latino, and
others).

Research Design
An exploration of the FDA-approved NMEs for 2010 and 2020 was done on the FDA
website. Inclusion and exclusion criteria were utilized to choose the FDA-approved NMEs in
2010 and the FDA-approved NMEs in 2020.
Inclusion criteria included the following:


All the FDA-approved NMEs in 2010 and 2020 that have adequate published
demographic data from the clinical trials conducted for the FDA-approved NMEs and
that were used for the New Drug Application (NDA) submission for the approval of the
drugs.
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Each of the FDA-approved NMEs in 2010 and 2020 should have demographic profiles
such as age range; sex: male/female; race: White, Black, Asian, mixed/ multiple races,
and others; and ethnicity: Hispanic/Latino, Non-Hispanic/Latino, and others.



All FDA approved NMEs in 2010 and 2020 that are meant for pediatric and adult
patients.
Exclusion criteria:



FDA-approved NMEs in 2010 and 2020 that were only for one single gender/sex either
males or females.



FDA-approved NMEs in 2010 and 2020 that are for pediatric patients only.

Data Collection
All the demographic data were gathered from the clinical trials conducted for the FDAapproved NMEs in 2010 and 2020. All the available demographic data, such as age, sex, race,
and ethnicity, were gathered from the clinical trials that were conducted for the FDA-approved
NMEs in 2010 and 2020. Some of the data for the FDA-approved NMEs in 2010 and 2020 were
excluded because a few of the FDA-approved NMEs were repeated on the FDA website. In this
instance, only one of each FDA-approved NME that was repeated was used for the results and
analysis.
All the FDA approved NMEs from 2010 and 2020 were identified on the FDA website:
Drugs@FDA: FDA-Approved Drugs (FDA, 2020; FDA, 2010). For each of the FDA-approved
NMEs in 2010, the demographic data were accessed from the Drugs@FDA: FDA-Approved
Drugs (FDA, 2010) on the website in the section of the “Original Approvals or Tentative
Approvals,” which includes link to the review section that links to the Drug Approval Package
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section. The Drug Approval Package section has several links to access the clinical trials that
were conducted and used for New Drug Application (NDA) submission for each of the FDAapproved NMEs in 2010. The clinical trial summary data for the FDA-approved NMEs can be
found in the Statistical reviews, Medical reviews, and other reviews.
The percentages for each demographic variable (e.g., race, White) that were pertinent to
this study were gathered for the results and analysis. The percentages of each of the demographic
variables for each NDA study were added together, and the average percentages were calculated
for each FDA-approved NME in 2010 for the results and analysis.
The FDA-approved NMEs in 2020 were identified from the Drugs@FDA: FDAApproved Drugs. The demographic data that were utilized for the NDA submission were
accessed from the Drug Trials Snapshots website (FDA, 2021; FDA, 2020). At the end of the
page of the website, there is a section for more information on all the demographic data collated
from the clinical trials conducted for the FDA-approved NME. The average total percentages of
each demographic variable (e.g., race, White) that are relevant to this study were gathered for the
results and analysis. The percentages of each of the demographic variables for each NDA study
were added together, and the average percentages were calculated for each FDA-approved NME
in 2020 for results and analysis.
All the FDA-approved NMEs in 2010 and 2020 were identified and documented; all the
indications and age ranges of the FDA-approved NMEs can be found in Appendix B, Appendix
D and Appendix E. Most of the drugs have different indications, but some of the FDA-approved
NMEs were repeated on the FDA website; the repeated NMEs had similar data, and only one of
each of the FDA-approved NME was used for the result and analysis. The FDA-approved NMEs
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that did not have reported data and the FDA-approved NMEs without adequate data on race and
ethnicities were excluded from the results and analysis.
The published demographic data in the clinical trials conducted for the approval of the
FDA NMEs were identified and were collated in Microsoft Excel spreadsheets and Microsoft
Word. They were all reported in percentages, and the average percentages for each demographic
variable for each year were calculated to get the final results. For this study, there was a
comparison of the findings for 2010 and 2020.

DEMOGRAPHIC PROFILES OF CLINICAL RESEARCH PARTICIPANTS
Results
All the demographic data for this thesis were from the FDA website. The demographic
data were accessed from the published data of the clinical trials/pivotal studies that were
conducted for the 61 FDA-approved NMEs in 2010 and 2020.
Table1 shows the FDA approved NMEs in 2010 and 2020, and the number of the
NDA/NMEs that contributed data to the analysis, and the number that were excluded.
Table 1
Identification and Selection of NDAs and NMEs
Number of NDAs/NMEs
selected by year.
Total number of FDA
approved NDAs/NMEs.
The number that did not have
required data
The number that did not meet
the inclusion and exclusion
criteria by reason (single sex,
pediatric)
The number that were
excluded for other reasons*
Number of NDA/NMEs that
contributed data to the
analysis

Year 2010

Year 2020

16

45

2

1

4

7

3

4

7

33

*The number of the FDA-approved NDA/NMEs that were repeated on the FDA website, and
only one of each of the repeated FDA-approved NMEs was used for data gathering and
contributed to the analysis of the final result.

16
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From the Table 1, the number of the FDA NDAs/NMEs that contributed to the data
analysis was seven FDA-approved NMEs in 2010 and 33 FDA-approved NMEs in 2020, making
a total number of 40 FDA-approved NMEs in both 2010 and 2020.
All the 61 FDA-approved NMEs in 2010 and 2020; the NMEs indications, age ranges,
and sex (male/female) can be found on the FDA website, the label section of the Drugs@FDA:
FDA-approved Drugs (FDA, 2020; FDA, 2010), and they are documented in Appendix D and
Appendix E. A list of the 61 FDA-approved NMEs and their generic names can be found in
Appendix B.
Table 2 lists the FDA-approved NMEs that contributed data to the analysis and the ones
that were excluded in 2010.
Table 2
Trade and Generic Names of Included and Excluded FDA-Approved NMEs in 2010
FDA Approved NMEs in 2010 (Included)

FDA Approved NMEs in 2010 (Excluded)

1. Ampyra (dalfapridine)

1. Asclera (polidocanol)

2. Gilenya (fingolimod hydrochloride)

2. Carbaglu (carglumic acid)

3. Laftacaft (alcaftadine)*

3. Ella (ulipristal acetate)

4. Latuda (lurasidone hydrochloride)

4. Halaven (eribulin mesylate)

5. Pradaxa (dabigatran etexilate mesylate)*

5. Jevtana Kit (carbazitaxel)

6. Teflaro (ceftaroline fosamil)*

6. Natazia (estradiol valerate; dienoget)

7. Victoza (liraglutide recombinant)
*Three FDA-approved NMEs in 2010 were repeated twice on the FDA website; only one of each
of the NMEs was used for data gathering and results.
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Table 3 lists the FDA-approved NMEs in 2020 that contributed to the data for analysis
and the ones that were excluded.
Table 3
Trade and Generic Names of Included and Excluded NMEs in 2020
FDA approved NMEs in 2020 (Included)
1. Ayvakit (avapritinib)
2. Barhemysys (amisulpride)
3. Byfavo (remimazolam besylate)
4. Detectnet (copper dotatate cu-64)
5. Dojolvi (triheptanoin)
6. Evrysdi (cisdiplam)
7. Gavreto (pralsetinib)*
8. Gemtesa (vibegron)
9. Imcivree (setmelanotide acetate)
10. Inqovi (cedazuridine; decitabine)
11. Isturisa (osilodrostat Phosphate)
12. Klisyri (tirbanibulin)
13. Nextletol (bempedoic acid)
14. Nexlizet (bempedoic acid; ezetimibe)
15. Nurtec ODT(remegepant sulfate)
16. Olinvyx (oliceridine)
17. Orladeyo (berotralstat hydrochloride)
18. Ongentys (opicapone)
19.Oxlumo (lumasiran sodium)
20.Pemazyre (pemigatinib)
21.Pizensy (lactitol)
22.Qinlock (ripretinib)
23.Retevmo (selpercatinib)
24.Rukobia (fostemsavir tromethamine)
25.Tabrecta (captatimib hydrochloride)
26.Tauvid (flortaucipir f-18)
27.Tazverik (tazemetostat)
28.Tukysa (tucatinib)
29.Veklury (remdesivir)
30.Winlevi (clascoterone)

FDA approved NMEs in 2020 (Excluded)
1. Artesunate (artesunate)*
2. Cetrianna (fluoroestradiol-f-18)
3. Gallium Ga 68 PSMA-11(gallium ga 68
psma-11)*
4. Koselugo (selumetinib sulfate)
5. Lampit(nifurtimox)
6. Orgovyx (relugolix)
7. Viltepso (viltolarsen)
8. Zokinvy (lonafarnib)

18
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31.Xeglyze (abametapir)*
32.Zeposia (ozanimod hydrochloride)
33.Zepleca (lurbinectedin)
*Four FDA-approved NMEs were repeated twice on the FDA website; only one of each NME
was used for the data gathering and results.
The list of the FDA-approved NMEs in 2010 and 2020, that contributed data to the
results and analysis in this study can be found in Appendix C.
Demographic Variables
Table 4 shows the demographic variables used for data gathering.
Table 4
Selected Demographic Variables
Sex
Male
Female

Race
White
Black
Asian
Other
Mixed/ Multiple races
Native Hawaiian
American Indian
Asian Pacific
Unknown

Ethnicity
Hispanic/ Latino
Non-Hispanic/
Latino
Not Reported
Unknown

Age
<65 years
≥65 years

There were variations in the reported age categories in all the published data for the
clinical trials conducted for the 40 FDA-approved NMEs in 2010 and 2020. The 40 FDAapproved NMEs did not have specific reported age categories. There were variations in the
published data for the age categories in the clinical trials for the 40 FDA-approved NMEs
because of the indications of the drugs and the age categories of the population that the drugs
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were indicated for. Only some of the 40 FDA-approved NMEs specifically reported on the age
categories of < 65 years and ≥ 65 years in the demographic profiles of the clinical trials that were
conducted for the FDA-approved NMEs, and there were variations in the published data.
Most of the clinical trials conducted for the 61 FDA-approved NMEs were multicenter
randomized controlled trials in the United States and other countries. A total of 40 FDAapproved NMEs in 2010 and 2020 contributed to the data analysis and the list can be found in
Appendix C.
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Table 5 shows the average percentages of demographic data representations for age, sex,
race and ethnicity of clinical trials participants in the clinical trials conducted for the seven FDAapproved NMEs in 2010 and 33 FDA-approved NMEs in 2020.
Table 5
FDA-Approved NMEs Demographic Profiles: 2010 and 2020
Demographic Profile

Year: 2010 (%)

Year: 2020 (%)

Age
<65 years

57.3%

65.3%

≥ 65 years

42.7%

34.3%

Male

47.6%

45.1%

Female

52.5%

54.9%

White

77%

77%

Black

9.7%

7.3%

Asian

4.3%

7.7%

Other

7.7%

2.9%

Multiple/Mixed Races

0%

0.1%

Native Hawaiian

0.0%

0.2%

American Indian

0.2%

0.4%

Asian Pacific

1.6%

0%

Unknown

0.1%

3.9%

Hispanic/Latino

5.7%

14.8%

Non-Hispanic/Latino

41.5%

72.1%

Not reported

0.6%

7.2%

Unknown

0%

4%

Sex/ Gender

Race

Ethnicity

DEMOGRAPHIC PROFILES OF CLINICAL RESEARCH PARTICIPANTS

22

Age
There were variations in the reported age categories across the whole spectrum in the
clinical trials conducted for seven FDA-approved NMEs in 2010 and the 33 FDA-approved
NMEs in 2020. The variations of the age categories depend on the indications of the drugs and
the age categories of the population that the drugs were developed for. Some of the FDAapproved NMEs were for both pediatric and adult patients, and some of the FDA approvedNMEs were for adult patients. The variations in the age categories occurred in the 40 FDAapproved NMEs in 2010 and 2020.
The specific age categories of < 65 years and ≥ 65 years were not reported in all the
clinical trials conducted for the FDA-approved NMEs in 2010 and 2020; there were variations in
the published demographic variables (age categories) in the clinical trials conducted for the
seven FDA-approved NMEs in 2010 and 33 FDA-approved NMEs in 2020. For the seven FDAapproved NMEs in 2010, the average percentage of representation for < 65 years was 57.3% and
for ≥ 65 years was 42.7%, while for the 33 FDA-approved NMEs the average percentage of
representations for < 65 years was 65.3% and for ≥ 65 years was 34.3%. There were variations in
the reported data for the < 65 years and ≥ 65 years old in the trials conducted for the 40 FDAapproved NMEs. The indications and the age categories of the FDA-approved NMEs in 2010
and 2020 are documented in Appendix D and Appendix E.
Four FDA-approved NMEs were excluded from the seven FDA-approved NMEs in 2010
for age calculations for < 65 years and ≥ 65 years because of the published data in 2010.
Nineteen FDA-approved NMEs were excluded from the 33 FDA-approved NMEs in 2020 for
the age calculations for < 65 years and ≥ 65 years because some of the NMEs did not have
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published data and some did not have the data for both < 65 years and ≥ 65 years in the clinical
trials conducted for the 40 FDA-approved NMEs in 2020.
Sex
The sex categories in this study consist of males and females. The males and females had
representation in the published demographic data from the clinical trials that were conducted for
seven FDA-approved NMEs in 2010 and 33 FDA-approved NMEs in 2020. From Table 5,
males had (47.6%) representation in the reported clinical trials that were conducted for the seven
FDA-approved NMEs, and females had (52.5%) representation in the reported clinical trials
conducted for the seven FDA-approved NMEs in 2010. The female representation was higher
(52.5%) than the male representation (47.6%) in the clinical trials conducted for the seven FDAapproved NMEs in 2010.
From Table 5, in 2020, male representation was (45.1%) while the female representation
was (54.9%) in the clinical trials that were conducted for the 33 FDA-approved NMEs. The
female representation was (54.9%) than the male representation (45.1%) in the clinical trials
conducted for the 33 FDA-approved NMEs in 2020.
Comparing the representations of the sex (males and females) in the clinical trials
conducted for the seven FDA-approved NMEs in 2010 and 33 FDA-approved NMEs in 2020,
the researcher found that female representations (52.5% and 54.9%) were both higher than the
male representations (47.6% and 45.1%).
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Race
There were variations in the race representation in all the clinical trials conducted for the
40 FDA-approved NMEs in 2010 and 2020. The reported race representations for the 40 FDAapproved NMEs were White, Black, Asian, mixed race/multiple races, Native Hawaiian, Asian
Pacific, American Indian, others, and unknown. From Table 5, the White clinical trial
participants had higher representation in the reported clinical trials conducted for the 40 FDAapproved NMEs in 2010 and 2020. In 2010, the White clinical trial participants had 77%
representation which was higher than the Black with 9.7%, Asian with 4.3%, others with 7.7%,
Native Hawaiian with 0.0%, Asian Pacific with 1.6%, American Indian with 0.2%, and unknown
race with 0.1% representation in the clinical trials that were conducted for the seven FDAapproved NMEs in 2010.
From the analysis of the results, from the demographic data that were collated from the
clinical trials that were conducted for the seven FDA-approved NMEs, the White trial
participants had higher representation in the clinical trials that were conducted for the seven
FDA- approved NMEs compared to Black clinical trial participants representation (9.7%), Asian
representation (4.3%), American Indians (0.2%) and other races (7.7%).
In 2020, the White clinical trial participants had higher representation (77%) than the
Black (7.3%), Asian (7.7%), others (2.9%), multiple races (0.1%), Native Hawaiian (0.2%),
American Indian (0.4%), and unknown races (3.9%) representation in the reported clinical trials
that were conducted for the 33 FDA-approved NMEs.
The demographic data that were collated from the clinical trials that were conducted for
the 33 FDA-approved NMEs; White clinical trial participants had higher representation (77%)
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than Black representation (7.3%), Asian representation (7.7%), American Indians (0.4%) and
other races (2.9%) representations in the clinical trials that were conducted for the 33 FDAapproved NMEs in 2020.
In addition, comparing the clinical trial participants’ representation in 2010 and 2020, the
White clinical trial participants had similar representation (77% and 77%) and were higher than
the rest of the racial and ethnic minorities in the clinical trials conducted for the seven FDAapproved NMEs and 33 FDA-approved NMEs in 2010 and 2020, respectively.
Ethnicity
There were variations in the reported data for the ethnic groups in the clinical trials
conducted for both the seven FDA approved NMEs in 2010 and 33 FDA-approved NMEs in
2020; this can account for variations in the average percentages of representations. The ethnic
groups consist of the Hispanic/Latino, non-Hispanic/Latinos, unknown, and “not reported
ethnicity” in some of the clinical trials that were conducted for the seven FDA-approved NMEs
in 2010 and 33 FDA-approved NMEs in 2020. From Table 5, the Hispanic/Latino had 5.7%
representation while the non-Hispanic/Latino had 41.5% representation in the clinical trials that
were conducted for the seven FDA-approved NMEs in 2010; in the same year, the unreported
ethnic group was 0.6%. Some of the FDA-approved NMEs in 2010 and 2020 did not have
published data on the ethnic groups of the clinical trial participants, some of them had missing
data, and there were inconsistencies in the published data for the ethnic groups.
In 2020, the Hispanic/Latino clinical trial participant representation was 14.8%, nonHispanic/Latinos’ representation was 72.1% in the clinical trials that were conducted for the 33
FDA-approved NMEs, the unreported ethnic minorities’ participant representation was 7.2%,
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and unknown ethnic group representation was 4% in the clinical trials that were conducted for
the 33 FDA-approved NMEs.
The ethnic minorities' representation in clinical trials conducted for both the seven FDAapproved NMEs and 33 FDA-approved NMEs were lower than the White participants’
representation in both years (2010 and 2020). Regarding the research question “Are racial/ethnic
minorities underrepresented in clinical trials?” from the results of this study, the White
participants had higher representation than the racial/ethnic minorities.
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Discussion
There were variations in the way the demographic data was reported for the clinical trial
participants in the clinical trials that were conducted for the seven FDA-approved NMEs in 2010
and 33 FDA-approved NMEs in 2020. The demographic data of the clinical trial participants in
the clinical trials were collated separately from the FDA website for each year and analyzed
separately. From the result, the White clinical trial participant representation was higher than the
racial and ethnic minorities, and the female clinical trial participants had higher representation
than the male trial participants in the clinical trial conducted for the 40 FDA-approved NMEs.
Comparing the demographic data that were collated from the clinical trials that were
conducted for the seven FDA-approved NMEs in 2010 and for the 33 FDA-approved NMEs in
2020, the researcher found that there were variations in the percentages of representation, and
indications of the FDA-approved NMEs are not the same. All the FDA-approved NMEs that
were used in this study are completely different from each other and they have different
indications and they can be found in Appendix D and Appendix E. There were variations in the
age categories in the reported clinical trials that were conducted for the seven FDA-approved
NMEs in 2010 and for the 33 FDA-approved NMEs; the age categories are dependent on the
groups of people that the drugs were developed for. Some of the age categories were < 65 years,
and ≥ 65 years were not reported in all the clinical trials conducted for both the seven FDAapproved NMEs in 2010 and the 33 FDA-approved NMEs in 2020 and there were variations.
In this study, the female representations were 52.5% and 54.9% in the collated data from
the reported clinical trials conducted for the seven FDA-approved NMEs and 33 FDA-approved
NMEs in 2010 and 2020, respectively. The female representation (52.5% and 54.9%) in the
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clinical trials conducted for the seven FDA-approved NMEs in 2010 and 33 FDA-approved
NMEs in 2020 were both higher than male representation (47.6% and 45.1%) in the clinical trials
conducted for the seven FDA-approved NMEs in 2010 and 33 FDA-approved NMEs in 2020,
respectively. The male representation was 47.6% in the clinical trials that were conducted for the
seven FDA-approved NMEs in 2010, and the male representation was 45.1% in the clinical trials
that were conducted for the 33 FDA-approved NMEs in 2020.
Moreover, from the results, there was a difference between the male representation and
female representation. The female representation was higher than the male representation in both
FDA-approved NMEs for both years (2010 and 2020). In this study, the analysis of the collated
results from the clinical trials conducted for the seven FDA-approved NMEs in 2010 and the 33
FDA-approved NMEs in 2020 with respect to the research question “Are women/females
underrepresented in clinical trials?” from the results of this study, the female representation was
higher than the male representation.
Furthermore, there were variations in the racial representation in the clinical trials
conducted for the seven FDA-approved NMEs in 2010 and 33 FDA-approved NMEs in 2020.
The White participants representation was higher (77% and 77%) in the clinical trials that were
conducted for the seven FDA-approved NMEs in 2010 and 33 FDA-approved NMEs in 2020,
respectively, when compared to Blacks (9.7% and 7.3%), Asians (4.3% and 7.7%), American
Indians (0.2% and 0.4%), Native Hawaiian (0.0% and 0.2%), and other races (7.7% and 2.9%)
representation in the clinical trials for the seven FDA-approved NMEs in 2010 and 33 FDAapproved NMEs in 2020, respectively. There were variations in the racial representations. With
respect to racial/ethnic minorities participation in the clinical trials in the FDA- approved NMEs
in 2010 and 2020, their representation was similar when compared to the White representation.
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In this study, the number of White clinical trial participants was higher than the
racial/ethnic minorities in this study. The racial/ethnic minorities are underrepresented in their
participation in the clinical trial during the drug development programs; these similar findings
have been reported in many articles, and the FDA recognizes this issue. The FDA has made
attempts to resolve this issue to increase and improve the participation of the racial and ethnic
minorities in clinical trials (George et al., 2014; Flores et al., 2021; Michos et al., 2021).
Furthermore, from the result of this study, the ethnic minorities, the Hispanics/Latino
(5.71% and 14.8%) and non-Hispanics/Latinos (41.5% and 72.1%) representations in the clinical
trials that were conducted for the seven FDA-approved NMEs in 2010 and 33 FDA-approved
NMEs in 2020 respectively were lower than the White clinical trials participants. Regarding the
research question “Has the demographic profile of clinical trial participants in drug development
(NME, NDA) studies changed from 2010 to 2020, especially with respect to racial/ethnic
minorities?” from the result of this study, the White trial participants had higher representation
than the racial/ethnic minorities, and this is the same trend for the FDA-approved NMEs in 2010
and 2020. The demographic profile of the clinical trial participants in drug (NME/NDA) studies
especially with respect to racial/ethnic minorities has been explained in the results section and
the published data of the representation of racial/ethnic minorities were lower when compared to
the White participants representation in the clinical trials conducted for the 40 FDA-approved
NMEs in 2010 and 2020. The low participation of the ethnic minorities has been reported in
several articles. The FDA is also aware of it and has tried to address the issue (George et al.,
2014; Flores et al., 2021; Michos et al., 2021).
Besides, it is critical to involve and increase the number of racial and ethnic minorities
participation in the clinical trials during the drug development programs because it will improve
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the diversity in the representations of diverse populations, which will help us to gain more
knowledge on the safety and efficacy of the drugs that are been developed, and it will also help
to improve the application of the drugs to a more heterogeneous population (George et al., 2014;
Flores et al., 2021; Michos et al., 2021).
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Conclusion
Clinical trials are a reliable source of quality information and scientific evidence that
provides high-quality solutions to scientific questions. This grants the relevant regulatory bodies
to evaluate the safety and efficacy of the novel drugs, and it also provides important information
to the medical professionals on how to utilize the new drugs which help the medical
professionals in the management of their patients. There are huge benefits in allowing more
diverse people to participate in trials, especially increasing the racial/ethnic minorities’
participants in trials, and it will enhance the knowledge regarding the diverse population in drug
development programs and will help to advance treatment choices. In the final analysis, this
study was done on 40 FDA-approved NMEs in 2010 and 2020; 21 FDA-approved NMEs were
excluded from analysis. The results from this study, the White trial participants had higher
representation than racial/ethnic minorities. Regarding the research question “Are racial/ethnic
minorities underrepresented in clinical trials?” from the results of this study, the White trial
participants’ representation was higher than the racial and ethnic minorities, and there is
similarity between the reported demographic profile of trial participants in the FDA-approved
NMEs in 2010 and 2020. This has been reported in several articles, and the FDA has also made
considerable efforts to address this issue (George et al., 2014; Flores et al., 2021; Michos et al.,
2021). Regarding the research question “Are women/females underrepresented in clinical trials?”
from the result of this study, the female representation was higher than the male representation in
this study.
Moreover, increasing and improving the recruitment and retention of racial/ethnic
minorities in clinical trials participation during the drug development program provides more
robust evidence regarding the pharmacokinetics, pharmacodynamics, safety, and efficacy of the
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new molecular entities across the whole spectrum of the demographic population. It is really
important to improve the recruitment and retention of all participants, particularly the racial/
ethnic minorities in the clinical trials during the drug development programs. This will also help
us to address the health disparities that affect the racial and ethnic minorities (Camidge, 2021).
The challenges of low recruitment and retention of racial/ethnic minorities in clinical trials can
be due to communication issues between the trial participants and research staff, transportation
issues (George et al., 2014), and the issue of mistrust between the trial participants and the
research staff (Corbie-Smith, 2002; George et al., 2014), etc. The ways to address these issues is
for research staff to modify their communication strategies to a culturally acceptable form for the
participants; this will increase clinical trial participation (George et al., 2014; Yankey et al.,
2006). Researchers can also provide some transportation or subsidize the costs of participants’
transportation for them to participate in the trials.
The limitations of this study include the limited number of FDA-approved NMEs that
were collated; some of the FDA-approved NMEs did not have adequate reported data on all the
required demographics; and some of the FDA-approved NMEs in 2010 and 2020 demographic
variables, such as age categories of trial participants, were not uniform and some were not
available.
Recommendations
Finally, there is a compelling need for further research on the demographic profiles of
clinical trial participants to further understand the heterogeneous population and increase the
sponsors’ and researchers’ knowledge of the reason why the clinical trial participants might be
interested in participating in clinical trials and also the reason why they may not be interested in
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participating in clinical trials. Having a more equitable, robust, and diverse population in clinical
trials will further enhance the sponsors’ and researchers’ knowledge of the safety and efficacy of
novel therapeutics, and this will support the use of the novel drugs in a more diverse population.
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Appendix A: Demographic Variables and Categories
Age category
•

< 65

•

≥ 65

•

Female

•

Male

Sex

Race
•

White

•

Black or African- American

•

Asian

•

American Indian or Alaska Native

•

Native Hawaiian or other Pacific islander

•

Multiple races

•

Asian Pacific

•

Other races

•

Unknown

Ethnicity
•

Hispanic/Latino

•

Latino

•

Non-Hispanic

•

Others

•

Unknown

•

Not Reported
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Appendix B: FDA-Approved NMEs 2010 and 2020
FDA-approved NMEs in 2010
Number &

FDA NME: Name of the

Active Ingredients/ Generic Name

Year: 2010.

Drug

1.

Ampyra

dalfampridine

2.

Asclera

polidocanol

3.

Carbaglu

carbaglumic acid

4.

Ella

ulipristal acetate

5.

Gilenya

fingolimod hydrochloride

6.

Halaven

eribulin mesylate

7.

Jevtana kit

cabazitazel

8.

Lastacaft*

alcaftadine

9.

Lastacaft*

alcaftadine

10.

Latuda

lurasidone hydrochloride

11.

Natazia

estradiol valerate; dienogest

12.

Pradaxa*

dabigatran etexilate mesylate*

13.

Pradaxa*

dabigatran etexilate mesylate*

14.

Teflaro*

ceftaroline fosamil*

15.

Teflaro*

ceftaroline fosamil*

16.

Victoza

liraglutide recombinant

*FDA approved NMEs that were repeated on the FDA website.
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FDA-approved NMEs in 2020
Number &
Year: 2020

FDA NME: Name of the Drug

Active Ingredients/Generic Name

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.

Artesunate*
Artesunate*
Ayvakit
Barhemsys
Byfavo
Cerianna
Detectnet
Dojolvi
Evrysdi
Gallium GA-68 psma-11*

artesunate*
artesunate*
avapritinib
amisulpride
remimazolam besylate
fluoroesteadiol f-18
64copper dotatate cu-64
triheptanoin
risdiplam
gallium ga-68 psma-11*

11.
12.
13.
14.
15.
16.
17.

Gallium GA-68 psma-11*
Gavreto*
Gavreto*
Gemtesa
Imcivree
Inqovi
Isturisa

gallium ga-68 psma-11*
pralsetinib*
pralsetinib*
vibegron
setmelanotide acetate
cedarudine; decitabine
osilodrostat phosphate

18.

Klisyri

tirbanibulin

19.
20.

Koselugo
Lampit

selumetinib sulfate
nifurtimox

21.

Nexletol

bempedoic acid

22.

Nexlizet

bempedoic acid; ezetimibe

23.

Nurtec ODT

rimegepant sulfate

24.

Olinvyk

oliceridine

25.

Orgovyx

relugolix

26.

Orladeyo

berotralstat hydrochloride

27.
28.
29.
30.
31.
32.

Ongentys
Oxlumo
Pemazyre
Pizensy
Qinlock
Retevmo

opicapone
lumasiran sodium
pemigatinib
lactitol
ripretinib
selpercatinib
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33.

Rukobia

fostemsavir tromethamine

34.
35.
36.
37.
38.
39.
40.
41.
42.

Tabrecta
Tauvid
Tazverik
Tukysa
Veklury
Viltepso
Winlevi
Xeglyze*
Xeglyze*

capmatinib hydrochloride
flortaucipir- f-18
tametostat hydrochloride
tucatinib
remdesivir
viltolarsen
clascoterone
abametapir*
abametapir*

43.
Zeposia
ozanimod hydrochloride
44.
Zepzelca
lurbinectedin
45.
Zokinvy
lonafarnib
*FDA approved NMEs that was repeated on the FDA website.
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Appendix C: FDA-Approved NMEs (2010 and 2020) Included in Study
Number
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.

FDA Approved NME in 2010
Ampyra (dalfapridine)
Gilenya (fingolimod hydrochloride)
Laftacaft (alcaftadine)
Latuda (lurasidone hydrochloride)
Pradaxa (dabigatran etexilate
mesylate)
Teflaro (ceftaroline fosamil)
Victoza (liraglutide recombinant)

FDA Approved NME in 2020
Ayvakit (avapritinib)
Barhemysys (amisulpride)
Byfavo (remimazolam besylate)
Detectnet (copper dotatate cu-64)
Dojolvi (triheptanoin)
Evrysdi (cisdiplam)
Gavreto (pralsetinib)
Gemtesa (vibegron)
Imcivree (setmelanotide acetate)
Inqovi (cedarudine; decitabine)
Isturisa (osilodrostat phosphate)
Klisyri (tirbanibulin)
Nexletol (bempedoic acid)
Nexlizet (bempedoic acid; ezetimibe)
Nurtec ODT (remegepant sulfate)
Olinvyx (oliceridine)
Orladeyo (berotralstat hydrochloride)
Ongentys (opicapone)
Oxlumo (lumasiran sodium)
Pemazyre (pemigatinib)
Pizensy (lactitol)
Qinlock (ripretinib)
Retevmo (selpercatinib)
Rukobia (fostemsavir tromethamine)
Tabrecta (captatimib hydrochloride)
Tauvid (flortaucipir f-18)
Tazverik (tazemetostat)
Tukysa (tucatinib)
Veklury (remdesivir)
Winlevi (clastcoterone)
Xeglyze (abametapir)
Zeposia (ozanimod hydrochloride)
Zepleca (lurnonafarnib binectedin)
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Appendix D: FDA-Approved NMEs (2010): Name and Indication
1. AMPYRA (dalfampridine): is a potassium channel blocker indicated to improve walking
in adult patients with multiple Sclerosis (MS). This was demonstrated in walking speed.
2. ASCLERA (polidocanol): Age: 18 years or older, it is a sclerosing agent indicated to
sclerose uncomplicated spider veins (varicose veins ≤1mm in diameter) and
uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower
extremity. Asclera has not been studied in varicose veins more than 3 mm in diameter.
3. CARBAGLU (carbaglu): Age- Pediatric and Adult patients. It is a carbamoyl phosphate
synthetase 1 (CPS 1) activator indicated in pediatric and adult patients as: Adjunctive
therapy to standard of care for the treatment of acute hyperammonemia due to Nacetylglutamate (NAGS) deficiency. Maintenance therapy for the treatment of chronic
hyperammonemia due to NAGS deficiency. Adjunctive therapy to standard of care for
the treatment of acute hyperammonemia due to propionic acidemia (PA) or methyl
malonic acidemia (MMA).
4. ELLA (ulipristal acetate): Age group, 16 years and over. It is a progesterone agonist/
antagonist emergency contraceptive for prevention of pregnancy following unprotected
intercourse or unknown or suspected contraceptive failure. Ella is not intended for
routine use as a contraceptive.
5. GILENYA (figolimod hydrochloride): Age for 10 years and older. It is a sphingosine 1phosphate receptor modulator indicated for the treatment of patients with relapsing forms
of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the
accumulation of physical disability.
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6. HALAVEN (eribulin mesylate): Age- Adults. It is a microtubule inhibitor indicated for
the treatment of patients with metastatic breast cancer who have previously received at
least two chemotherapeutic regimens for the treatment of metastatic disease. Prior
therapy should have included an anthracycline and a taxane in either the adjuvant or
metastatic setting.
7. JEVTANA (cabazitaxel): Age: Adults, men. It is a microtubule inhibitor indicated in
combination with prednisolone for treatments of patients with hormone-refractory
metastatic prostate cancer previously treated with a docetaxel-containing treatment
regimen.
8. LAFTACAFT* (alcaftadine): Age- 2 years and older. It is a H1 histamine receptor
antagonist indicated for the prevention of itching associated with allergic conjunctivitis.
9. LATUDA (lurasidone hydrochloride): Age- 13 years and older. It is an atypical
antipsychotic for the treatment of Schizophrenia, depressive episodes associated with
Bipolar I disorder (bipolar depression), as monotherapy and as adjunctive therapy with
lithium or valproate.
10. NATAZIA (estradiol valerate; dienogest): Age- Women of child bearing age. It is an
estrogen/progestin COC, indicated for use by women to prevent pregnancy. The efficacy
of Natazia in women with a body mass index (BI) of >30 kg/m2 has not been evaluated.
11. PRADAXA* (dabigatran etexilate mesylate): Age- Adults and Paediatric patients aged 8
years or older. It is a direct thrombin inhibitor indicated to reduce the risk of stroke and
systemic embolism in patients with non-valvular atrial fibrillation.
12. TEFLARO* (ceftaroline fosamil): Age- Adult and Pediatric patients (at least 34 weeks
gestational age and 12 days postnatal age and older). It is a cephalosporin antibacterial
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indicated for the treatment of the following infections caused by designated susceptible
bacteria: Acute bacterial skin and skin structure infections (ABSSSI), communityacquired bacterial pneumonia (CABP).
13. VICTOZA (liraglutide recombinant): Age- Adults and children (10 years of age and
older). It is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated- as an adjunct
to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,
to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes
mellitus and established cardiovascular disease.

*The FDA approved NMEs that were repeated twice on the FDA website.
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Appendix E: FDA-Approved NMEs (2020): Name and Indication
1. ARTESUNATE* (artesunate): Age- Adult and pediatric patients, it is an antimalarial
indicated for the initial treatment of severe malaria in adult and pediatric patients.
Treatment of severe malaria with Artesunate for injection should always be followed by a
complete treatment course of an appropriate oral antimalarial regimen.
2. AYVAKIT (avapritinib) is a kinase inhibitor indicated for: Age- 18 years and older. It is
used for: Gastrointestinal Stromal Tumor (GIST): the treatment of adults with
unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha
(PDGFRA) exon18 mutation, including PDGFRA D842V mutations. Advanced Systemic
Mastocytosis (AdvSM): the treatment of adult patients with AdvSM. AdvSM includes
patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an
associated hematological neoplasm (SM AHN), and

mast cell leukemia (MCL).”

3. BARHEMSYS (amisulpride): Age- 18 years and older. It is a dopamine-2 (D2)
antagonist indicated in adults for Prevention of postoperative nausea and vomiting
(PONV) either alone or in combination with an antiemetic of a different class. Treatment
of PONV in patients who have received antiemetic prophylaxis with an agent of a
different class or have not received prophylaxis.
4. BYFAVO (remimazolam besylate): Age- Adults 18 years and older, it is for injection is a
benzodiazepine indicated for the induction and maintenance of procedural sedation in
adults undergoing procedures lasting 30 minutes.
5. CERIANNA (fluoroesteadiol f-18): is a drug for the visual detection of estrogen receptor
(ER)-positive lesions in addition to tissue biopsy in patients with recurrent or metastatic
breast cancer.
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6. DETECTNET (copper dotatate cu-64): Age- Adult patients. DETECTNET is a drug for
detection of the specific type of tumors called somatostatin receptor positive neuroendocrine tumors (NETs) in adults. NETs are rare tumors that develop in certain
hormone-producing cells of the body’s neuro-endocrine system.
7. DOJOLVI (triheptanoin): Age- pediatric and adult patients. DOJOLVI is a drug that
provides calories and fatty acids for pediatric and adult patients with long-chain fatty acid
oxidation disorder. Long-chain fatty acid oxidation disorders (LC-FAOD) are a group of
rare, genetic, life threatening disorders caused by defects in the enzymes needed to
produce the energy from fatty acids. Patients with LC-FAODs can suffer from muscle
pain, fatigue, and heart failure because their bodies break down muscle as a source of
energy as fat cannot be used as an energy source.
8. EVRYSDI (risdiplan): is a drug for the treatment of spinal muscular atrophy (SMA) in
patients 2 months of age and older. Spinal muscular atrophy is a rare genetic disease that
affects mostly children and young adults. It is caused by a low level of protein in the
motor neurons that are responsible for normal muscle functioning. The lack of protein
causes motor neuron loss, progressive muscle weakness, and may lead to premature death
from respiratory failure.
9. GALLIUM GA 68 PSMA-11* (gallium ga-68 psma-11): Ga 68 PSMA-11 is a drug used
for detection of specific cancer lesions in men with prostate cancer whose newly
diagnosed cancer could be cured with the initial treatment, or who have been treated for
prostate cancer but have high prostate-specific antigen (PSA) in their blood. High PSA in
the blood of these patients is a suspicious sign that cancer is coming back or spreading.
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10. GAVRETO* (pralsetinib): is a drug used to treat adult patients with non-small cell lung
cancer (NSCLC) which has spread to other parts of the body (metastatic) and is caused
by abnormal RET (rearranged during transfection) genes.
11. GEMTESA (vibegron): Age range: Adults patients. It is used to treat the following
symptoms due to a condition called overactive bladder (OAB): a strong need to urinate
with leaking or wetting accidents, the need to urinate right away, and the need to urinate
often.
12. IMCIVREE (setmelanotide acetate): is a drug used for long-lasting weight management
in patients 6 years and older who are obese because of a specific enzyme deficiency
[(proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1),
or leptin receptor (LEPR) deficiency)].
13. INQOVI (cedazuridine; decitabine): is used to treat adults with myelodysplastic
syndromes (MDS) including chronic myelomonocytic leukemia. MDS is a type of blood
cancer in which blood cells in the bone marrow are defective leading to a low number of
one or more types of blood cells.
14. ISTURISA (osilodrostat phosphate): is a drug for the treatment of adults with Cushing’s
disease: who cannot have pituitary gland surgery, or who have had pituitary gland
surgery, but the surgery did not cure their Cushing

disease. Cushing’s disease is a rare

disease in which the adrenal glands make too much of the cortisol hormone because of
stimulation from a pituitary tumor.
15. KLISYRI (tirbanibulin): Age- 18 years and older. It is used on the skin to treat patients
with actinic keratosis on the face or scalp. Actinic keratosis is a common skin disease
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caused by long-term exposure to the sun and/or indoor tanning. If left untreated, AK may
progress to skin cancer.
16. KOSELUGO (selumetinib sulfate): is used to treat children 2 years of age and older with
a type of tumor called plexiform neurofibroma or PN that occurs in a rare disease called
neurofibromatosis type 1 (NF1). It is used in patients whose tumors cause symptoms and
could not be surgically removed.
17. LAMPIT (nifurtimox): It is drug used to treat Chagas disease in children less than 18
years old. Chagas disease is an infectious disease caused by a parasite (Trypanosoma [T.]
cruzi). After years of infection, the parasites may cause serious and sometimes deadly
heart conditions as well as serious gut and nerve damage.
18. NEXLETOL (bempedoic acid): Age- Adults. It is a drug for the treatment of high LDL
cholesterol, which is sometimes referred to as “bad cholesterol”. NEXLETOL is to be
used in the following two groups of patients: (1) Adult patients with an inherited
condition called heterozygous familial hypercholesterolemia (HeFH) or (2) patients with
complications from too much cholesterol (known as atherosclerotic cardiovascular
disease – ASCVD), such as hearts and strokes.
19. NEXLIZET (bempedoic acid; ezetimibe): Age- 18 years and older. It contains an
adenosine triphosphate-citrate lyase (ACL) inhibitor and a cholesterol absorption
inhibitor, is indicated as an adjunct to diet and maximally tolerated statin therapy for
treatment of adults with heterozygous familial hypercholesterolemia or established
atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
20. NURTEC ODT (rimegepant sulfate): Age- 18 years and older. NURTEC ODT is a drug
used for treatment of acute migraine with or without aura in adults.
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21. OLINVYK (oliceridine): Age- Adult patients, 18 years and older. It is a drug for the
treatment of acute pain in adults when the pain is severe enough to require an intravenous
opioid.
22. ORGOVYX (relugolix): is a drug for the treatment of adults with advanced prostate
cancer.
23. ORLADEYO (berotralstat hydrochloride): is a drug used to prevent attacks of hereditary
angioedema (HAE) in patients 12 years and older. Hereditary angioedema is a rare,
inherited and sometimes life-threatening condition with repeat episodes (attacks) of
severe swelling in various parts of the body, including stomach, limbs, face and throat.
24. ONGENTYS (opicapone): Age- Adults. It is a drug used to treat patients with
Parkinson’s disease (PD) who are having “off” episodes while taking drugs (levodopa
and carbidopa) for the treatment of Parkinson’s disease. An “off” episode is a time when
a patient’s medications are not working well, leading to an increase in Parkinson’s
symptoms, such as tremor and difficulty walking.
25. OXLUMO (lumasiran sodium): is a drug used to lower the level of urine oxalate in
children and adults with primary hyperoxaluria type 1 (PH1). PH1 is a rare, inherited
disorder in which the liver makes too much oxalate. Excess oxalate can lead to kidney
stones and kidney damage. Over time, oxalate can also build up in the body and damage
other organs, including the heart, bones and eyes.
26. PEMAZYRE (pemigatinib): is a drug used for treatment of adults with bile duct cancer
(cholangiocarcinoma) that has spread to other parts of the body (metastatic) or cannot be
removed by surgery. It should be used in patients who have been previously treated with
chemotherapy and whose cancer has a certain type of abnormality in the FGFR2 gene.
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27. PIZENSY (lactitol): is used to treat a type of constipation called chronic idiopathic
constipation (CIC) in adults.
28. QINLOCK (ripretinib): is drug used to treat adult patients with gastrointestinal stromal
tumor (GIST) whose disease: cannot be surgically removed or, has spread throughout the
body (metastatic GIST), and has been treated with at least three prior treatments. GIST is
type of stomach, bowel, or oesophagus tumour.
29. RETEVMO (selpercatinib): is a drug used to treat certain cancers caused by abnormal
RET (rearranged during transfection) genes in: Adult patients with non-small cell lung
cancer (NSCLC) which has spread to other parts of the body (metastatic). Adults and
children 12 years of age and older with advanced or metastatic medullary thyroid cancer
(MTC). Adults and children 12 years of age and older with advanced or metastatic
thyroid cancer who have received radioactive iodine that did not work or is no longer
working.
30. RUKOBIA (fostemsavir tromethamine): Age- 18 years and older. It is a drug for the
treatment of human immunodeficiency virus-1 (HIV-1) infection in adults who have
received several anti-HIV-1 regimens in the past, and have HIV-1 virus that is resistant to
many antiretroviral medicines, and who are failing their current antiretroviral therapy
because it is not effective, have intolerable side effects or other safety problems.
31. TABRECTA (capmatinib hydrochloride): TABRECTA is a drug used to treat adult
patients with a type of non-small cell lung cancer (NSCLC) which: has a specific gene
mutation (mesenchymal epithelial transition or MET mutation) and, has spread to other
parts of the body (metastatic).
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32. TAUVID (flortaucipir f-18): Tauvid is a drug for the visual detection of aggregated
neurofibrillary tangles or NFTs in the brain of adult patients with suspected Alzheimer’s
disease (AD). NFTs are deposits of tau protein that are present in the brains of patients
with AD. Alzheimer’s disease is a common degenerative disease of the brain that starts
with mild thinking, judging and memory problems and progresses to dementia and death.
33. TAZVERIK (tazemetostat hydrochloride): is a drug used to treat a type of cancer called
advanced epithelioid sarcoma. It is to be used in patients 16 years and older when cancer
has spread and cannot be completely removed by surgery. Epithelioid sarcoma is a rare,
slow growing type of cancer that begins in the soft tissues of the body (most commonly
under the skin of an extremity)
34. TUKYSA (tucatinib): is a drug for treatment of adults with human epidermal growth
factor receptor (HER) 2-positive breast cancer that has spread to other parts of the body
including the brain (metastatic) or cannot be removed by surgery. It should be used in
patients who have been previously treated for their metastatic disease with at least one
anti-HER2 regimen and in combination with two other medications for the treatment of
metastatic breast cancer (trastuzumab and capecitabine).
35. VEKLURY (remdesivir): Age: 12 years and older, it is for use in adult and pediatric
patients 12 years and older weighing at least 40 kg (88 lbs) for the treatment of
coronavirus disease 2019 (COVID-19) requiring hospitalization.COVID-19 is an
infectious, potentially serious or life-threating respiratory disease caused by a coronavirus
called SARS-CoV-2 virus.
36. VILTEPSO (viltolarsen): Age- ages 4 years to 17 years old. It is a drug for the treatment
of a particular type of Duchenne muscular dystrophy (DMD). It is to be used only in
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patients who have a specific mutation of the dystrophin gene. DMD is a rare disease that
primarily affects boys. It is caused by low levels of a muscle protein called dystrophin.
The lack of dystrophin causes progressive muscle weakness and premature death.
37. WINLEVI (clascoterone): is used on the skin to treat acne vulgaris in patients 12 years
and older. Acne vulgaris is a skin disease characterized by oily skin, blackheads or
whiteheads, pimples, and sometimes scarring.
38. XEGLYZE* (abametapir): Age- 6 months of age and older. For topical use only, It is a
lotion applied once to dry hair.” “It is should be used in the context of an overall lice
management program: Wash (with hot water) or dry-clean all recently worn clothing,
hats, used bedding and towels. Wash personal care items such as combs, brushes and hair
clips in hot water. Use a fine-tooth comb or special nit comb to remove dead lice and nits.
39. ZEPOSIA (ozanimod hydrochloride): is a drug used for the treatment of adults with
relapsing forms of multiple sclerosis (RMS) including: clinically isolated syndrome,
relapsing-remitting disease, and active secondary progressive disease.
40. ZEPZELCA (fluoroesteadiol f-18): is a drug used to treat adult patients with small cell
lung cancer (SCLC) which has spread to other parts of the body (metastatic) on or after
treatment with platinum-containing therapy.
41. ZOKINVY (lonafarnib): is a drug used in patients one year of age and older with a
certain body surface area to lower the risk of death in Hutchinson-Gilford Progeria
Syndrome (HGPS), or to treat certain processing-deficient progeroid laminopathies.
*FDA approved NMEs that were repeated twice on the FDA website.

